Stockholm Market Grows on AstraZeneca Earnings Beat & Sagax’s Real‑Estate Expansion
Stockholm markets rise modestly as AstraZeneca beats earnings and Sagax AB expands its income‑generating real‑estate portfolio.
3 minutes to read
Sagax A
Sagax A’s 710 M SEK Cross‑Border Deal: Stable Rent, Global Diversification & Strategic Growth
Discover how Sagax A’s €710 M cross‑border acquisition delivers stable 53 M SEK annual income, deep diversification, and growth upside amid regulatory and FX risks.
5 minutes to read
Sagax AB: Brokerage Cut Targets Amid Modest Earnings – What It Means for Investors
Explore Sagax AB’s latest valuation shift: modest profit lift, dividend hike, and cautious broker revisions amid Swedish real‑estate dynamics and ESG risks.
4 minutes to read